Bimatoprost for the management of vitiligo: A systematic review and meta‐analysis

This systematic review and meta-analysis evaluated the effectiveness and safety of bimatoprost, a prostaglandin F2-alpha analogue, for treating vitiligo. The study included 8 studies with 111 patients, primarily with non-segmental vitiligo. Bimatoprost, used alone or in combination with other therapies like NB-UVB phototherapy and FxCO2 laser, showed potential for significant repigmentation and patient satisfaction. Bimatoprost monotherapy achieved the highest repigmentation rates, while combination therapies showed over 50% repigmentation. Relapse rates were low, and patient satisfaction was high. However, limitations include a small sample size and varied protocols. Bimatoprost is considered a promising treatment for vitiligo, especially in combination therapies, but further studies are needed to confirm its long-term efficacy.